|
|
Volumn 1, Issue 7, 2002, Pages 491-492
|
|
Selective anticancer drugs. Market indicators
a
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE;
ANTINEOPLASTIC AGENT;
BCR ABL PROTEIN;
BEVACIZUMAB;
CANERTINIB;
CETUXIMAB;
CISPLATIN;
DOXORUBICIN;
EPIDERMAL GROWTH FACTOR RECEPTOR;
ERLOTINIB;
ETOPOSIDE;
FLUOROURACIL;
FLUTAMIDE;
GEFITINIB;
IMATINIB;
MATUZUMAB;
MDX 210;
METHOTREXATE;
MONOCLONAL ANTIBODY;
PACLITAXEL;
PELITINIB;
PERTUZUMAB;
PLATELET DERIVED GROWTH FACTOR RECEPTOR;
PROTEIN KINASE C;
RITUXIMAB;
STEM CELL FACTOR;
TAMOXIFEN;
TGDCC E1A;
TRASTUZUMAB;
UNCLASSIFIED DRUG;
UNINDEXED DRUG;
CANCER SURVIVAL;
CHRONIC MYELOID LEUKEMIA;
CLINICAL TRIAL;
COST EFFECTIVENESS ANALYSIS;
DNA SYNTHESIS;
DRUG COST;
DRUG RESEARCH;
DRUG RESPONSE;
DRUG TARGETING;
ENZYME ACTIVITY;
ENZYME INHIBITION;
GENE OVEREXPRESSION;
HUMAN;
LUNG NON SMALL CELL CANCER;
NOTE;
ONCOGENE NEU;
PRIORITY JOURNAL;
PROTEOMICS;
QUALITY OF LIFE;
SIGNAL TRANSDUCTION;
ARTICLE;
DRUG DESIGN;
ECONOMICS;
NEOPLASM;
ANTINEOPLASTIC AGENTS;
DRUG DESIGN;
HUMANS;
NEOPLASMS;
|
|
EID: 0036636073
PISSN: 14741776
EISSN: None
Source Type: Journal
DOI: 10.1038/nrd842 Document Type: Note |
|
Times cited : (81)
|
|
References (4)
|
